International Journal of Mental Health and Addiction
November 28, 2023
Tayler Holborn, Robert L. Page, Fabrizio Schifano et al.
5 citations
Abstract Currently, novel psychoactive substance (NPS) use presents a challenging issue for authorities. To effectively tackle the use of NPS, a deeper understanding of the motivations of those who use NPS is required. Evidence suggests that a subset of NPS users declare their use as ‘self-medicating’; however, there is a paucity of research in this area. The aim of this review is to provide an...
Frontiers in Psychiatry
November 23, 2023
Florian Buchmayer, Siegfried Kasper
19 citations
Intranasal esketamine for treatment-resistant depression has been introduced and approved by the FDA and EMA in 2019 and 2020, respectively. Since then, the administration practices were found different among countries. Major depression has a high impact on many humans lives worldwide and more than a third of treated people are not responding after several treatment attempts. Additional...
Trials
November 23, 2023
Grace Branjerdporn, Kerri Gillespie, Elizabeth A Martin et al.
1 citation
Perinatal women are highly vulnerable to developing mental health issues and particularly susceptible to a recurrence of psychiatric illness. Poor mental health during the perinatal period can have long-term impacts on the physical and psychiatric health of both mother and child. A potentially useful strategy to improve women's mental health is through a mobile application teaching mindfulness,...
The MIT Press eBooks
November 21, 2023
Gautier Dassonneville
1 citation
In this chapter, I examine the undocumented history of mescaline in medical and psychiatric circles in France by reconstructing the scientific context in which Jean-Paul Sartre's famous bad trip took place in February 1935. 1 In this way, we can first consider that the very term "bad trip," sometimes ascribed to the experience retrospectively 2 on the basis of accounts by Simone de Beauvoir...
Journal of Psychedelic Studies
November 20, 2023
Tahlia R. Harrison
23 citations
Abstract Background and aims Psychedelic-assisted therapy (P-AT) has been shown to reduce post-traumatic stress disorder (PTSD), depression, and anxiety symptoms, and is likely to be approved in the United States (US) in the coming years. However, concerns about participant safety in these early trials have surfaced, including allegations of sexual misconduct. This paper aims to illuminate how...
Journal of Medicinal Chemistry
November 20, 2023
Kaveh Matinkhoo, Lisa Yu, David Press et al.
18 citations
The psychedelic prodrug psilocybin has shown therapeutic benefits for the treatment of numerous psychiatric conditions. Despite positive clinical end points targeting depression and anxiety, concerns regarding the duration of the psychedelic experience produced by psilocybin, associated with enduring systemic exposure to the active metabolite psilocin, pose a barrier to its therapeutic...
European Psychiatry
November 17, 2023
Kerem Böge, Inge Hahne, Niklas Bergmann et al.
Introduction The therapeutic effectiveness of mindfulness-based interventions (MBIs) has been shown for various mental disorders. However, for schizophrenia spectrum disorders (SSD), only a few trials have been conducted, mostly in outpatient settings. Objectives This study aimed to investigate feasibility, acceptability, and preliminary effectiveness of a four-week mindfulness-based group...
European Psychiatry
November 17, 2023
K. Beck, Atheeshaan Arumuham, S. Brugger et al.
1 citation
Introduction N-Methyl-D-Aspartate Receptor (NMDAR) hypofunction is hypothesised to underlie psychosis but this has not been tested early in illness. Objectives Our aim was to determine if NMDAR availability was lower in patients with first episode psychosis compared to healthy controls. Methods To address this, we studied 40 volunteers (21 patients with first episode psychosis and 19 matched...
European Psychiatry
November 17, 2023
M. I. Husain, Daniel M. Blumberger, David Castle et al.
Introduction During the last decade there has been a resurgence of interest on the use of psychedelics as novel treatments for mental disorders, including treatment-resistant depression (TRD). Psilocybin, the chemical component of “magic mushrooms”, has been administered with psychotherapy in randomized clinical trials (RCTs) showing large and sustained antidepressant effects. As the use of...
Psychoactives
November 17, 2023
Anna Beatriz Vicentini, Lucas Silva Rodrigues, Giordano Novak Rossi et al.
4 citations
Alcohol is the recreational drug most frequently consumed, and its high frequency of use can lead to worsening social, psychological, and domestic issues. The age group most susceptible to alcohol dependence is 18- to 24-year-old youths, demanding interventional tools to target early involvement risks. Ayahuasca seems to be a promising therapeutic tool since evidence suggests it presents...